% | $
Quotes you view appear here for quick access.

Dendreon Anonim Ortaklik Message Board

  • goldman321 goldman321 Mar 3, 2014 4:31 PM Flag

    DNDN, going to $10 this month. All shorts will be burnt out!

    Let's see.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Yes. We see that combinations have really had an upswing since Zytiga and Xtandi came onto the market and we think that certainly with our data that has come out on PROVENGE, abiraterone. We currently have the study with PROVENGE Xtandi. We see more and more combinations and views. And again and I just want to reemphasize that immunotherapy was such an incredible hallmark at ASCO-GU this year and it was said over and over again from some of the big names such as James Gulley and Charles Drake, immunotherapy first, PROVENGE first and then hormonal manipulation thereafter.

      Sentiment: Strong Buy

    • I'm not going to comment on the overall year-over-year growth in urology but as I said, we saw urology bounce back in terms of the strength of growth there in enrollments thus far in the first quarter. I think you will see these fluctuations from time to time inside of these accounts for various reasons as well as just patient flows. But there hasn't been any signal certainly that I've seen that says that urology is going to slow down or decline. I mean all the feedback we've received from the customers has been positive and if anything we've heard that the urology community intends to use the product more this year than they have in past years.

      Sentiment: Strong Buy

    • We have cash, cash equivalents and short and long-term investments at December 31, 2013 of approximately $199.4 million. Our restructuring plan is enabling us to slow our cash burn and be better positioned to achieve profitability while continuing to make strategic investments and initiatives that we believe will create value for our shareholders, physicians and patients. Our goal remains to get our cash flows and balance sheet aligned.

      Sentiment: Strong Buy

    • As we look ahead, we expect our Q1 2014 revenues to be consistent with our Q1 2013 results. This will make Q1 the first quarter since the introduction of competition where we see revenues to be stable or growing as compared to the prior year. As you know, it is not unusual for Q1 to be slightly behind Q4 due to seasonality, but we believe that our expectations for Q1 demonstrate an overall stabilization of our business.

      Sentiment: Strong Buy